Clinical trials are an important way to improve treatment for people with cancer. While most are continuing during the COVID-19 pandemic, the period of time that clinical trials are available and recruiting may change quickly. If you would like to get involved in a clinical trial, speak to your treatment team or the health service where the clinical trial is being undertaken, to confirm it is open and appropriate for you. For cancer information and support, call Cancer Council's experienced cancer nurses on 13 11 20 Monday to Friday from 9am-5pm.

MASTERPLAN : A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease

Male or<br/>FemaleGender Male or
Female

RecruitingStatus Recruiting

Radiotherapy<br/>TrialTypeRadiotherapy
Trial

TwoPhase Two

18-75Age 18-75

Pancreas<br/>CancersCancer LocationPancreas
Cancers

Radiotherapy,Surgical,Systemic therapy | Stomach and upper gastrointestinal tractPancreas

Trial Overview Read MoreRead more

This phase II trial is trying to understand whether adding high precision radiotherapy to chemotherapy and surgery will improve treatment outcomes for patients with pancreatic cancer.
 

This trial is treating patients with pancreatic cancer.

This is a radiotherapy, chemotherapy and surgical trial.

You may be excluded from this trial if:

  • You have a certain disease or psychological condition.
  • You have been diagnosed with a prior or secondary type of cancer.
  • You have had certain treatments, surgical procedures or drugs.

Clinical trials have complex eligibility criteria - talk to your doctor about your interest in this trial.

Clinical Summary Read MoreRead more

Trial Identifiers

Use the hyperlinks, where available to access additional clinical trial information.

Scientific Title

A Randomised Phase II Study of MFOLFIRINOX And Stereotactic Radiotherapy (SBRT) for Pancreatic Cancer With High Risk and Locally Advanced Disease

Cooperative Group

Australasian Gastro-Intestinal Trials Group (AGITG)

Other Non-Commercial Sponsor

Australian Government Department of Health, Medical Research Future Fund (MRFF)

Summary

Eligible patients will be randomised into one of two groups; both of which will undergo a chemotherapy regimen, containing either a mFOLFIRINOX or Gemcitabine/Nab-paclitaxel drug combination. Only one group will go on to receive stereotactic radiotherapy, before potentially undergoing surgery.

Recruiting Hospitals Read MoreRead more

Peter MacCallum Cancer Centre, Radiation Oncology
Parkville
Parkville Research
RadOnc.Research@petermac.org

Trial Overview: General information about a clinical trial. This section provides an overview of who might be able to join this trial and what type of treatment is involved.

Next